|
WO2020172584A1
|
|
Solid polymorphs of a flna-binding compound and its hydrochloride salts
|
|
CA2999268A1
|
|
Cocrystals of naloxone and naltrexone
|
|
CA2999509A1
|
|
Crystalline salts of naloxone and naltrexone
|
|
US2016081946A1
|
|
4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
|
|
AU2015200090A1
|
|
Micronized opioid compositions, formulations and dosage forms and methods of making same
|
|
US2015148318A1
|
|
Method for inhibiting growth of cancer cells
|
|
WO2014028755A1
|
|
Benzazocine-ring compound inhibition of tau hyperphosphorylation
|
|
EP2872899A1
|
|
Alzheimer's disease assay in a living patient
|
|
EP2882428A2
|
|
A method of inhibiting tau phosphorylation
|
|
EP2918587A2
|
|
Filamin A binding compounds and their use as anti-inflammatory and analgesic agents
|
|
AU2009308769A1
|
|
Filamin A-binding anti-inflammatory analgesic
|
|
CA2779261A1
|
|
Filamin a binding anti-inflammatory and analgesic
|
|
WO2010051374A1
|
|
Analgesic that binds filamin a
|
|
AU2008335351A1
|
|
Methods for conducting a clinical trial
|
|
CA2959274A1
|
|
Micronized opioid compositions, formulations and dosage forms and methods of making same
|
|
WO2009076231A1
|
|
Dissolution test equipment and methods for testing
|
|
WO2009059225A2
|
|
Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin a
|
|
WO2009058737A1
|
|
Disposable column system for purification of radiolabeled polypeptides
|
|
US2009203722A1
|
|
Novel compositions and methods for enhancing potency or reducing adverse side effects of opiold agonists
|
|
US2005245557A1
|
|
Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
|
